Discussions focused on disrupting barriers to innovation with evidence and collaborations; generating and reporting evidence; evidence in FDA and payer decision-making; and defining standard of care in wound care clinical trials and clinical practice.
Meeting’s 130 participants included thought leaders from the FDA, CMS, NIH, health systems, industry, clinicians, and payers.
— WCCC Chair and SAWC Spring Planning Committee member Dr. Vickie R. Driver
MALVERN, PENNSYLVANIA, UNITED STATES, May 21, 2024 /EINPresswire.com/ — HMP Global’s Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society (WHS) partnered with the Wound Care Collaborative Community to host the inaugural Driving Innovation in Wound Care Summit, addressing public policy challenges related to assuring patients receive access to wound-healing therapies.
The Summit was held Monday, May 13 at the Orlando World Center Marriott in Orlando, prior to the May 14-18 SAWC Spring | WHS meeting. An invited group of stakeholders discussed barriers to wound care innovation and science-based, patient-centered solutions to overcome barriers together.
“This year’s inaugural Driving Innovation in Wound Care Summit marks a crucial milestone in our collective mission, including the FDA, CMS, and NIH,” said WCCC Chair and SAWC Spring Planning Committee member Vickie R. Driver, DPM, MS, FACFAS. “It underscores the urgency and importance of our work at the WCCC to revolutionize wound care practices. Through our initiatives and unwavering commitment, WCCC is driving transformative change in the field of wound care, and the Summit serves as a pivotal platform to accelerate these efforts.”
Participants included representatives from the Food and Drug Administration (FDA), Centers for Medicare & Medicaid Services (CMS), National Institutes of Health (NIH), WCCC’s membership, leading clinicians, researchers, industry, health systems, and payers. Discussions focused on disrupting the barriers to innovation with evidence and collaborations; generating and reporting evidence; real-world evidence in FDA and payer decision-making; and defining standard of care in wound care clinical trials and clinical practice.
“It was an honor to collaborate with the WCCC on this critical event with many leaders collaborating and brainstorming for a shared mission,” said Tiffney Oliver, Vice President, Wound Care Learning Network, HMP Global. “Initiatives like this are crucial to ensuring future innovation and patient-centered solutions for the field of wound care.”
The premier supporter was Organogenesis Inc. Supporters included MIMOSA Diagnostics, Mölnlycke Health Care, MolecuLight Inc., Imbed Biosciences Inc., MediWound, Kerecis, Convatec Inc., Reapplix, MIMEDX Group, Inc., NOxy Health Products, Reprise Biomedical, Essity, and BioLab Sciences. Contributors included ARANZ Medical, Aroa Biosurgery Limited, BiogenCell LTD, GR Consulting, medaxis, Oneness Biotech Co., Ltd., SolasCure, and Urgo Medical North America.
“Organogenesis was proud to sponsor and participate in the Wound Care Collaborative Community’s inaugural Driving Innovation in Wound Care Summit,” said Kurt Matheson, Vice President, Marketing, Organogenesis Inc. “Collaborative events and dialogue such as this between key healthcare community stakeholders will play a critical role in supporting the development of future technologies needed to positively impact patients. We look forward to a continued partnership with the WCCC on pursuing innovations that make all the difference.”
SAWC Spring | WHS is the leading meeting dedicated to the management, treatment, and prevention of wounds. For more information, visit sawcspring.com.
ABOUT WOUND CARE COLLABORATIVE COMMUNITY
The Wound Care Collaborative Community (WCCC) is an FDA-approved and recognized Collaborative Community focused on stimulating wound care innovation to improve product safety and patient access to cutting-edge medical technology while reducing cost and time to the market. The WCCC acts as a focal point for collaboration between the various parts of the wound care community and works closely together with the FDA and CMS on medical device, drug, and biologic challenges to achieve common objectives and outcomes that are squarely focused on removing the barriers to innovation for patients. For more information, visit woundcarecc.org.
ABOUT HMP GLOBAL
HMP Global is the omnichannel market leader in healthcare events, education, and insight — with a mission to improve patient care. For 40 years, the company has built trusted brands including Psych Congress, the premier source for mental health education, and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. HMP Global partners with leading experts around the world to deliver more than 450 annual events, medical strategy, and marketing for pharmaceutical and medical device customers through HMP Collective, and pharmaceutical market insight, engaging a global community of healthcare stakeholders that includes nearly 2 million clinicians across 600 medical specialties as well as managed care, behavioral health, senior living, emergency medical, and pharmaceutical commercialization professionals. For more information, visit hmpglobal.com.
Sandi Beason, APR
HMP Global
+1 601-573-1737
email us here
Visit us on social media:
Facebook
LinkedIn
